Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Ajman Government Media Office hosts Foreign Affairs Undersecretary at THE SIGNAL with a clear message: ‘The UAE does not seek the signal – it creates it’

    November 22, 2026

    Humaid bin Ammar attends day two of Ajman Media Forum 2026 and honours participants and partners

    November 22, 2026

    Ajman Government Media Office’s THE SIGNAL forum features Saeed Al Eter on how public trust and a successful development model underpin UAE soft power in times of crisis

    November 22, 2026
    Facebook X (Twitter) Instagram
    UAE IndependentUAE Independent
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    UAE IndependentUAE Independent
    Home » Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
    ACCESS Newswire

    Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

    March 26, 2024
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    • mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222
    • Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and COVID-19, mRNA-1083

    CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company’s next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna’s licensed COVID-19 vaccine.

    “We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, further validating our robust mRNA platform,” said Stéphane Bancel, Chief Executive Officer of Moderna. “mRNA-1283 is a critical component of our combination vaccine against flu and COVID-19, mRNA-1083, and this milestone gives us confidence in our ability to bring this much needed vaccine to market.”

    In the NextCOVE (NCT05815498) Phase 3 pivotal trial, mRNA-1283 was shown to elicit a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2, compared to mRNA-1273.222. Importantly, this benefit was most acutely seen in participants over the age of 65 years, the population that remains at highest risk for severe outcomes from COVID-19. The most common solicited local adverse event was injection site pain. The most common solicited systemic adverse events included headache, fatigue, myalgia and chills.

    The NEXTCove clinical trial is a randomized, observer-blind, active-controlled study of approximately 11,400 individuals aged 12 years and older in the United States, United Kingdom and Canada. mRNA-1283 was found to have a similar safety profile to Moderna’s approved COVID-19 vaccines.

    The storage, shelf life and pre-filled syringe presentation of mRNA-1283 could alleviate healthcare provider burden and potentially increase access into new settings to serve public health. A detailed analysis of the Phase 3 clinical trial data for mRNA-1283 will be shared at the Company’s Vaccines Day event on March 27 and presented at upcoming scientific conferences.

    About Moderna

    Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

    Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

    Spikevax® is a registered trademark of Moderna.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential longer refrigerator shelf life and storage advantages of mRNA-1283 compared to Spikevax; and the ability of mRNA-1283 to maintain effectiveness compared to Spikevax. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

    Moderna Contacts

    Media:
    Elise Meyer
    Sr. Director, Corporate Communications
    +1 617-852-7041
    Elise.Meyer@modernatx.com

    Investors:
    Lavina Talukdar
    Senior Vice President & Head of Investor Relations
    +1 617-209-5834
    Lavina.Talukdar@modernatx.com

    SOURCE: Moderna, Inc.

    View the original press release on accesswire.com

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities

    November 20, 2026

    Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities

    November 17, 2026

    Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations

    November 10, 2026
    Latest News

    Guinea declares mpox outbreak over after 42 days without cases

    Health November 21, 2026

    Guinea has declared an end to its mpox outbreak after two full incubation periods passed with no new active cases or chains of transmission. The government made the announcement on Thursday, November 19. Health Minister Khaite Sall said in an

    WFP seeks $12.1 billion to feed 91 million people in 2027

    November 21, 2026

    South Korea’s exports pass $1 trillion for the first time

    November 21, 2026

    Air Arabia Egypt launches Cairo to Al Ain flights now

    November 20, 2026

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026
    © 2026 UAE Independent | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.